Syncona (SYNC) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free SYNC Stock Alerts GBX 110.60 -0.40 (-0.36%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 3, 2024 | lse.co.ukLONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTecApril 11, 2024 | lse.co.ukSyncona agrees to sell stake in investee company for GBP7.4 millionApril 9, 2024 | markets.businessinsider.com4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing CapacityApril 8, 2024 | markets.businessinsider.comOMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah TeichmannMarch 14, 2024 | lse.co.ukSyncona portfolio company Autolus posts widened loss for 2023February 21, 2024 | finanznachrichten.deFreeline Therapeutics Holdings plc: Acquisition of Freeline by Syncona Becomes EffectiveFebruary 10, 2024 | thetimes.co.ukShortlist revealed for NED awardsFebruary 8, 2024 | finanznachrichten.deBioNTech SE: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage ProgramsFebruary 8, 2024 | lse.co.ukSyncona portfolio strengthens in third quarter thanks to AutolusFebruary 8, 2024 | lse.co.ukUPDATE: Syncona portfolio strengthens thanks to AutolusJanuary 19, 2024 | lse.co.ukSyncona says Freeline trial for Gaucher disease treatment positiveDecember 14, 2023 | bbc.comSynconaDecember 4, 2023 | markets.businessinsider.comSyncona Portfolio Firm Beacon's AGTC-501 Trial Shows Positive Data In X-Linked Retinitis PigmentosaNovember 23, 2023 | msn.comBRIEF-Syncona Ltd To Acquire Freeline TherapeuticsNovember 22, 2023 | marketwatch.comFreeline Therapeutics Shares Rise on Takeover by SynconaNovember 22, 2023 | msn.comGene Therapy Player Freeline Therapeutics Goes Private In $28M DealNovember 22, 2023 | marketwatch.comFreeline Therapeutics Agrees to Buyout by SynconaNovember 22, 2023 | markets.businessinsider.comFreeline Therapeutics To Be Bought By Syncona For $28.3 Mln In Cash; Freeline Stock UpNovember 22, 2023 | msn.comFreeline Therapeutics to be acquired by Syncona for $28.3M in cashNovember 22, 2023 | finance.yahoo.comSyncona to Acquire Freeline TherapeuticsNovember 16, 2023 | lse.co.ukSyncona reports declining asset value as investment head steps downOctober 18, 2023 | markets.businessinsider.comSyncona Proposes To Acquire Freeline TherapeuticsOctober 18, 2023 | msn.comFreeline gains on non-binding buyout offer from SynconaOctober 18, 2023 | marketwatch.comSyncona Seeks to Buy Remaining Shares of Freeline TherapeuticsOctober 16, 2023 | finance.yahoo.comSwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating OfficerOctober 16, 2023 | marketwatch.comSyncona Portfolio Company to Present Updated Data on Cancer StudyOctober 4, 2023 | finanznachrichten.deSwanBio Therapeutics: SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathyOctober 4, 2023 | finance.yahoo.comSwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathySeptember 29, 2023 | marketwatch.comSyncona to Buy Back Up to GBP40 Mln in SharesSeptember 27, 2023 | tmcnet.comForcefield Therapeutics appoints John Tsai MD as Chief Executive OfficerSeptember 12, 2023 | msn.comNovartis recalls Sandimmune oral solution due to crystal formationSeptember 11, 2023 | uk.investing.comFTSE 250 movers: Vistry surges, Syncona sinks on write-offSeptember 11, 2023 | thetimes.co.ukSyncona downcast as eye treatment is discontinuedSeptember 11, 2023 | uk.finance.yahoo.comUK's Syncona writes off 54.5 million stg after Novartis ends Gyroscope's therapySeptember 11, 2023 | lse.co.ukSyncona suffers negative valuation hit as Novartis discontinues GT005September 11, 2023 | reuters.comUPDATE 1-UK Stocks-Factors to watch on Sept 11September 11, 2023 | reuters.comUK's Syncona writes off 54.5 mln stg after Novartis ends Gyroscope's therapySeptember 6, 2023 | markets.businessinsider.comPurespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People OfficerAugust 17, 2023 | msn.comTruist Securities Maintains Autolus Therapeutics plc - ADR (AUTL) Buy RecommendationAugust 2, 2023 | finance.yahoo.comPurespring Therapeutics appoints Sachin Kelkar as Chief Financial Officer following appointment of Julian Hanak as Chief Executive OfficerAugust 2, 2023 | technews.tmcnet.comOMass Therapeutics Expands Leadership Team with Two New AppointmentsJune 15, 2023 | thetimes.co.ukSyncona is not in good shapeJune 15, 2023 | marketwatch.comSyncona Swung to FY 2023 Pretax Loss; To Deploy GBP150 Mln-GBP200 Mln in CapitalJune 13, 2023 | tmcnet.comBeacon Therapeutics launches with £96 million ($120 million)June 9, 2023 | msn.comPharma giant AstraZeneca signs huge deal with UK start-up to create treatments for diabetes and other autoimmune diseasesJune 9, 2023 | lse.co.ukTOP NEWS: AstraZeneca hails deal with Quell; positive danicopan dataMay 29, 2023 | finance.yahoo.comSYNC.L - Syncona LimitedMay 12, 2023 | msn.comChardan Capital Maintains Achilles Therapeutics Plc - ADR (ACHL) Buy RecommendationApril 19, 2023 | benzinga.comOMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio ProgressApril 13, 2023 | thetimes.co.ukBiotech is in Britain’s DNA but still needs investment Get Syncona News Delivered to You Automatically Sign up to receive the latest news and ratings for SYNC and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. SYNC Media Mentions By Week SYNC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYNC News Sentiment▼0.000.79▲Average Financial Services News Sentiment SYNC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYNC Articles This Week▼00▲SYNC Articles Average Week Get Syncona News Delivered to You Automatically Sign up to receive the latest news and ratings for SYNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABDN News Today STJ News Today JGGI News Today RCP News Today MNKS News Today HICL News Today TRIG News Today BUR News Today INPP News Today PHLL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:SYNC) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syncona Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
